Retrophin (RTRX) PT Raised to $40 at BMO Capital

Retrophin (RTRX) PT Raised to $32 at Leerink Partners Following Clear Efficacy from Sparsentan

Leerink Partners analyst Joseph Schwatz reiterated an Outperform rating and boosted his price target on Retrophin (NASDAQ: RTRX) to $32.00 (from $27.00) after the company announced positive top-line results for Phase 2b DUET study of sparsentan in focal segmental glomerulosclerosis (FSGS) this morning and they spoke with... More

Ligand Pharma (LGND) Says Retrophin (RTRX) Presented Sparsentan Phase 2 Study Data

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) partner Retrophin, Inc. (Nasdaq: RTRX) announced positive top-line results from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder without an approved pharmacologic treatment that often leads to end-stage renal disease. The study achieved statistical significance in the primary efficacy endpoint for the overall sparsentan treatment group, demonstrating a greater than two-fold reduction of proteinuria compared to irbesartan after the eight-week, double-blind treatment period.

Retrophin has reported notable top-line results... More

Ligand Pharma (LGND) Gains After Retrophin (RTRX) Announces Positive Sparsentan Phase 2 Data

Ligand Pharma (NASDAQ: LGND) gained Wednesday after Retrophin (Nasdaq: RTRX) announced positive top-line results from the Phase 2 DUET study of sparsentan for the treatment of FSGS.

Retrophin previously secured a license to sparsentan from Ligand Pharmaceuticals and Bristol-Myers Squibb Company.

Retrophin (RTRX) Announces Significant Top-Line Data from Sparsentan Phase 2 as FSGS Treatment

Retrophin, Inc. (Nasdaq: RTRX) announced positive top-line results from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder without an approved pharmacologic treatment that often leads to end-stage renal disease. The study achieved statistical significance in the primary efficacy endpoint for the overall sparsentan treatment group, demonstrating a greater than two-fold reduction of proteinuria compared to irbesartan after the eight-week, double-blind treatment period.

We are very pleased with the robust top-line results from DUET, which suggest sparsentan could be a significant... More

Roth Capital Positive on Ligand Pharma (LGND) Ahead of Sept. Catalysts; Affirms at 'Buy'

Roth Capital affirms Ligand Pharmaceuticals (Nasdaq: LGND) with a Buy rating and $149 price target today and offers to remind investors about catalysts coming up this month, which includes the
Phase IIb sparsentan data in FSGS patients being developed by partner Retrophin (Nasdaq:... More